Global /Canada /Healthcare /Biotechnology /RIZE

Rize Oncology Inc.

RIZE

• CSE: RIZE • Delayed

0.0300CAD -40%

0.0215 USD

As of 10 June 2026, Rize Oncology Inc. has a market cap of $1.63M USD, ranking #47604 globally and #2531 in Canada. It ranks #4222 in the Healthcare sector, and #824 in the Biotechnology industry.

Global Rank

47604

Country Rank

2531

Sector Rank

4222

Industry Rank

824

Key Stats

Market Cap

$1.63MUSD

2.27M CAD

Enterprise Value

$430.22KUSD

600.4K CAD

Net Income (TTM)

-$568.13KUSD

-792.69K CAD

PB Ratio

1.4

Company Profile

Country (HQ)

Canada

Sector

Healthcare

Industry

Biotechnology

CEO

Roland Boivin open_in_new

Founded

2018

Website

rizeoncology.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-40%	0%	-50%	-70%	-70%	-67%	20%	-91%	-96%

News

Markets

Exchange	Ticker	Price	Quotes
Canadian Securities Exchange (CSE) MIC: XCNQ PRIMARY	RIZE Rize Oncology Inc ISIN: CA76971M1068 Shares Out.: Shares Outstanding: 75.745M¹ Shares Float: 9.113M² TV: TradingView: CSE: RIZE SA: Stock Analysis: CSE: RIZE YF: Yahoo Finance: RIZE.CN GF: Google Finance: CNSX: RIZE BA: Barron's: RIZE MS: Morningstar: XCNQ: RIZE	0.0300 CAD	TV: TradingView: CSE: RIZE SA: Stock Analysis: CSE: RIZE YF: Yahoo Finance: RIZE.CN GF: Google Finance: CNSX: RIZE BA: Barron's: RIZE MS: Morningstar: XCNQ: RIZE
OTC Markets (OTCMKTS / OTC) MIC: OTCM	RZONF Rize Oncology Inc ISIN: CA76971M1068 TV: TradingView: OTC: RZONF SA: Stock Analysis: OTC: RZONF YF: Yahoo Finance: RZONF GF: Google Finance: OTCMKTS: RZONF BA: Barron's: RZONF MS: Morningstar: PINX: RZONF	0.1600 USD	TV: TradingView: OTC: RZONF SA: Stock Analysis: OTC: RZONF YF: Yahoo Finance: RZONF GF: Google Finance: OTCMKTS: RZONF BA: Barron's: RZONF MS: Morningstar: PINX: RZONF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Rize Oncology Inc.

Rize Oncology Inc. engages in the development of oncology therapeutics. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada.

Similar Companies

Industry: Biotechnology (Canada)

Name	Market Cap (USD) diff.	PE	Country
Aurinia Pharmaceuticals Inc. NASDAQ: AUPH	$1.99B 122K%	7.4	Canada
AbCellera Biologics Inc. NASDAQ: ABCL	$1.16B 71K%	-	Canada
Eupraxia Pharmaceuticals Inc. TSX: EPRX	$430.66M 600.89M CAD 26K%	-	Canada
NervGen Pharma Corp. TSXV: NGEN	$293.99M 410.19M CAD 18K%	-	Canada
Cybin Inc. NEO: CYBN	$253.09M 353.13M CAD 15K%	-	Canada
Cardiol Therapeutics Inc. TSX: CRDL	$149.14M 208.08M CAD 9K%	-	Canada

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 11M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 10M%	19.0	United States
argenx SE EBR: ARGX	$47.72B 41.39B EUR 3M%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.68B 68.19T KRW 3M%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.39B 60.27B AUD 3M%	29.3	Australia
Lonza Group AG SIX: LONN	$42.26B 33.71B CHF 3M%	37.2	Switzerland

chevron_leftBack